Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.47 |
| ▸ | ACLY | P53396 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834398 | 0.91 | MAPT (0.47) | PGR | |
| SCHEMBL4834507 | 0.89 | PGR (0.43) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL4829022 | 0.88 | MAPT (0.49) | CYP3A4CYP2D6PGR | |
| SCHEMBL4836618 | 0.87 | MEN1 (0.42) | HTR6 | |
| SCHEMBL4833946 | 0.86 | KEAP1 (0.46) | PGRHTR6 | |
| SCHEMBL4825947 | 0.85 | MAPT (0.50) | CYP3A4 | |
| SCHEMBL4827030 | 0.85 | ALDH1A1 (0.47) | — | |
| SCHEMBL4833691 | 0.85 | PSEN1 (0.44) | CYP3A4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL4829045 | 0.85 | KMT2A (0.41) | PGRHTR6 | |
| SCHEMBL4830862 | 0.85 | PGR (0.44) | CYP3A4CYP2D6PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | CYP3A4 2352/4885CYP2D6 2559/4885PSEN1 2600/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | CYP3A4 1914/4885CYP2D6 1693/4885PSEN1 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.